{"name":"PharmaMar","slug":"pharma-mar","ticker":"PHM.MC","exchange":"Bolsa de Madrid","domain":"pharmamar.com","description":"PharmaMar is a Spanish pharmaceutical company headquartered in Colmenar Viejo, Madrid, Spain. Founded in 1986 as a subsidiary of Zeltia, it absorbed its parent company and all its subsidiaries in a reverse merger takeover in 2015. The company is a component of the Madrid Stock Exchange General Index (IGBM) and the IBEX 35 since 2020, after being part of the Ibex Small Cap stock market index.","hq":"Madrid, Spain","founded":0,"employees":"505","ceo":"José María Fernández Sousa-Faro","sector":"Oncology / Marine Biotech","stockPrice":89.3,"stockChange":3.7,"stockChangePercent":4.32,"marketCap":"$1.5B","metrics":{"revenue":280000000,"revenueGrowth":87.1,"grossMargin":94.5,"rdSpend":0,"netIncome":74986000,"cash":167223008,"dividendYield":0.93,"peRatio":20.8,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Yondelis patent cliff ($44.4M at risk)","drug":"Yondelis","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"Gemcitabine plus PM060184","genericName":"Gemcitabine plus PM060184","slug":"gemcitabine-plus-pm060184","indication":"Other","status":"phase_1"},{"name":"PM060184","genericName":"PM060184","slug":"pm060184","indication":"Other","status":"phase_2"},{"name":"Vincristine (VCR)","genericName":"Vincristine (VCR)","slug":"vincristine-vcr","indication":"Other","status":"phase_3"},{"name":"Zalypsis","genericName":"Zalypsis","slug":"zalypsis","indication":"Other","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Aplidin®","genericName":"Aplidin®","slug":"aplidin","indication":"Relapsed or refractory multiple myeloma","status":"phase_2"}]}],"pipeline":[{"name":"Aplidin®","genericName":"Aplidin®","slug":"aplidin","phase":"phase_2","mechanism":"Aplidin is a chemotherapeutic agent that works by inhibiting the enzyme histone deacetylase (HDAC).","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"Gemcitabine plus PM060184","genericName":"Gemcitabine plus PM060184","slug":"gemcitabine-plus-pm060184","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"PM060184","genericName":"PM060184","slug":"pm060184","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Vincristine (VCR)","genericName":"Vincristine (VCR)","slug":"vincristine-vcr","phase":"phase_3","mechanism":"Vincristine works by inhibiting microtubule formation in the mitotic spindle, resulting in cell cycle arrest at metaphase.","indications":[],"catalyst":""},{"name":"Zalypsis","genericName":"Zalypsis","slug":"zalypsis","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"PharmaMar Reports 2023 Full-Year Results","summary":"PharmaMar reported a net loss of €143.4 million for 2023, with revenue of €44.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"PharmaMar and Helsinn Partner to Develop New Cancer Therapies","summary":"PharmaMar and Helsinn announced a partnership to develop new cancer therapies, including a Phase 1 clinical trial for a new trabectedin-based treatment.","drugName":"","sentiment":"positive"},{"date":"2023-09-01","type":"regulatory","headline":"PharmaMar Receives FDA Approval for Yondelis in Soft Tissue Sarcoma","summary":"PharmaMar announced that the FDA has approved Yondelis (trabectedin) for the treatment of soft tissue sarcoma.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE12RWdhNGdPRG1UVFZ2bnIyMTdpZERLMnBId1hxSTN3ZU85VFpfZWpma09hYU1QTlh1YXJfZmVXSjZHM2FoRlk3LVVGODl4a1htTEYyQw?oc=5","date":"2021-04-16","type":"pipeline","source":"Yahoo Finance UK","summary":"Audax Renovables, S.A. (ADX.MC) stock price, news, quote and history - Yahoo Finance UK","headline":"Audax Renovables, S.A. (ADX.MC) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE9XVHhhOEdWajhDamx1cHJFSzl0Y1VjamZ3d1N3bmRLal9ibDM3Y2M2eGprRzNNZ0Z3NDVaS1NXQWlXNEY0alFOMk1OQ3o1eUNqVTBlWA?oc=5","date":"2017-05-22","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Pharma Mar, S.A. (PHM.MC) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Pharma Mar, S.A. (PHM.MC) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE5fLTk1UGVUOC0wSHlxeDktVU1OWENwUHR5eXEySm5lV3N4RWJYbVlqYXU5UHByNmVra05WN0V5WWN5a0p3T2tKQ2dEUnV1WUtjWHB1Xw?oc=5","date":"2017-05-20","type":"pipeline","source":"Yahoo Finance UK","summary":"Pharma Mar, S.A. (PHM.MC) stock price, news, quote and history - Yahoo Finance UK","headline":"Pharma Mar, S.A. (PHM.MC) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPVVUzeGpuODE1b0pHMWczWVVBNGlZalVOc0pocXExckMzbEJOa3lDdGg3VnFjVmF1QlFmeGJJM2NGZGRPWFdxdDVmeFJJX1lZYzlIQ3hWd2lzeV9pdHQ4MWpOSXlKeUdYTUxBUnIzdlJYZTlyOWdXaFNwVm04dk9scWFLRUlmQlE2M0xsYXFRV1BiR0dyY3owX2VHVDZaZ2ZGRkUyeGtyLWhodnlHd0N5c2xNTTlMOXM?oc=5","date":"2015-11-16","type":"pipeline","source":"The Pharma Letter","summary":"Zeltia restructures and rebrands as PharmaMar, Edison increases valuation | Pharmaceutical | The Pharmaletter - The Pharma Letter","headline":"Zeltia restructures and rebrands as PharmaMar, Edison increases valuation | Pharmaceutical | The Pharmaletter","sentiment":"neutral"}],"patents":[{"drugName":"Yondelis","drugSlug":"trabectedin","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":44400000}],"drugCount":5,"phaseCounts":{"phase_2":3,"phase_1":1,"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bayer","Merck KGaA","Pfizer"],"therapeuticFocus":["Oncology","Marine Biotech"],"financials":null,"yahoo":{"currentPrice":89.3,"previousClose":85.6,"fiftyTwoWeekHigh":102.4,"fiftyTwoWeekLow":70.1,"fiftyTwoWeekRange":"70.1 - 102.4","fiftyDayAverage":81.24,"twoHundredDayAverage":80.45,"beta":0.32,"enterpriseValue":1368228352,"forwardPE":12.5,"priceToBook":6.16,"priceToSales":6.99,"enterpriseToRevenue":6.18,"enterpriseToEbitda":20.59,"pegRatio":0,"ebitda":66468000,"ebitdaMargin":30,"freeCashflow":22879000,"operatingCashflow":53130000,"totalDebt":49415000,"debtToEquity":19.6,"currentRatio":3.02,"returnOnAssets":10.2,"returnOnEquity":32.6,"analystRating":"1.6 - Buy","recommendationKey":"buy","numberOfAnalysts":8,"targetMeanPrice":103.62,"targetHighPrice":120,"targetLowPrice":75,"dividendRate":0.8,"payoutRatio":0.19,"fiveYearAvgDividendYield":0,"exDividendDate":1750809600,"insiderHeldPercent":18.9,"institutionHeldPercent":8.4,"sharesOutstanding":17299232,"floatShares":13430748,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":4.3,"epsForward":7.17,"revenuePerShare":12.7,"bookValue":14.51,"officers":[{"age":null,"name":"Mr. Jose Maria Fernandez Sousa-Faro Ph.D.","title":"Founder, Executive Chairman, CEO & President"},{"age":null,"name":"Mr. Pedro Francisco Fernandez Puentes","title":"Executive Vice-Chairman"},{"age":76,"name":"Mr. Juan Carlos-Torres Carretero","title":"Founder"},{"age":null,"name":"Ms. María Luisa de Francia Caballero","title":"Chief Financial Officer"},{"age":null,"name":"Mr. José Luis Moreno Martinez-Losa","title":"Head of Capital Markets & Investor Relations"},{"age":null,"name":"Mr. Juan Gomez Pulido","title":"General Counsel & Secretary of the Board of Directors"},{"age":null,"name":"Ms. Sandra Llamera Sanchez","title":"Global Compliance Head"},{"age":null,"name":"Ms. Lara  Vadillo","title":"Communication Director"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.pharmamar.com","phone":"34 91 846 60 00"}}